Side-by-side · Research reference
IGF-DESvsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED8/60 cited
BPhase 3HUMAN-REVIEWED14/43 cited
IGF-DES
IGF-1 Analogue · Truncated N-Terminal
~10×Potency vs IGF-1
ReducedIGFBP binding
ResearchStatus
Injection (local or systemic) · Research protocols onlyBredehöft 2008
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
IGF-DES
Sermorelin
Pathway
IGF1R activation → PI3K/Akt & MAPK signaling → protein synthesis, proliferation
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Enhanced muscle protein synthesis, myoblast differentiation, reduced apoptosis, cell proliferation
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
Unknown — no human endocrine feedback data
Yes — short pulse preserves feedback
Origin
Synthetic truncation of native IGF-1 — removal of N-terminal Gly-Pro-Glu tripeptideBredehöft 2008
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
IGF-DES
Sermorelin
Research dose range
10–100 ng/mL (in vitro); μg doses (animal models)
Highly context-dependent; no standardized human protocol.
—
Route
Subcutaneous or intramuscular (local injection favored)
Local delivery maximizes tissue-specific uptake.
—
Frequency
Variable — daily to multiple times daily in research
Once daily, pre-sleep
Evidence basis
Animal models + in vitro only
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Human data
None — no clinical trials
—
Half-life
Shorter than IGF-1 due to reduced IGFBP binding
Rapid tissue uptake, limited systemic circulation.
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
Lower / starter dose
—
100 mcg per dose
Duration
—
8–12 weeks per cycle
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep, fasted preferred
03Metabolic / Fat Loss Evidence
Parameter
IGF-DES
Sermorelin
Primary mechanism
Indirect via muscle hypertrophy → metabolic rate elevation
—
Direct lipolysis
Minimal evidence — IGF-1 axis primarily anabolic, not lipolytic
—
Prostate model
Inhibited BPH cell proliferation when combined with vitamin D3 analogueCrescioli 2002
Context-specific anti-proliferative effect, not fat loss.
—
04Side Effects & Safety
Parameter
IGF-DES
Sermorelin
Hypoglycemia risk
Theoretical — IGF-1 axis enhances glucose uptake
—
Mitogenic risk
Chronic IGF-1 receptor activation may promote cell proliferation, potential tumor growthCrescioli 2002
—
Injection site reaction
Expected — erythema, irritation, local swelling
Mild erythema, transient pain
Edema / Fluid retention
Possible via sodium retention (IGF-1 axis effect)
—
Human safety data
Absent — no human trials, all effects theoretical or extrapolated
—
Unknown long-term effects
No chronic dosing studies in humans; endocrine, metabolic consequences unknown
—
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Pregnancy / OB
—
Avoid
Glucose handling
—
Generally neutral
Absolute Contraindications
IGF-DES
- ·Active malignancy or history of cancer (mitogenic risk)
- ·Pregnancy / lactation (no safety data)
- ·Hypoglycemia disorders
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
IGF-DES
- ·Diabetes mellitus (unpredictable glucose effects)
- ·Renal or hepatic impairment (clearance unknown)
- ·Edema-prone conditions (heart failure, nephrotic syndrome)
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
IGF-DES
Sermorelin
1. Research context only
Des(1-3)IGF-1 has no approved human protocol. All administration details are derived from animal or in vitro research and should not be construed as medical guidance.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Reconstitution (if lyophilized)
Sterile water or bacteriostatic water per research protocol. Gently swirl; do not shake. Store reconstituted peptide at 2–8 °C.
SQ — abdomen or thigh. Rotate sites.
3. Injection site
Subcutaneous (abdomen, thigh) or intramuscular (deltoid, vastus lateralis). Local injection to target tissue (e.g., muscle group) may enhance regional uptake.
Pre-sleep, fasted.
4. Timing
Frequency and timing vary by research design. Post-exercise or fasted state may theoretically enhance muscle uptake.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle gauge
27–31G insulin syringe for subcutaneous; 25–27G for intramuscular.
29–31G, 4–8 mm insulin syringe.
6. Monitoring
Glucose monitoring essential (hypoglycemia risk). No established IGF-1 or safety labs for human use.
—
06Stack Synergy
IGF-DES
+ BPC-157
ModerateDes(1-3)IGF-1 promotes myoblast differentiation and protein synthesis, while BPC-157 enhances tissue repair, angiogenesis, and collagen synthesis. Both act on distinct pathways (IGF1R vs gastric pentadecapeptide mechanisms) to support muscle recovery and connective tissue integrity. Synergy is mechanistic but lacks direct co-administration studies.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- BPC-157
- 250–500 mcg SQ, daily or twice daily
- Frequency
- Daily or per research protocol
- Primary benefit
- Accelerated muscle repair, enhanced hypertrophy, connective tissue support
+ TB-500
ModerateTB-500 (Thymosin Beta-4 fragment) promotes cell migration, angiogenesis, and wound healing via actin regulation. Des(1-3)IGF-1 drives protein synthesis and myoblast proliferation. Combined, these peptides may synergistically enhance muscle recovery, repair, and hypertrophy through complementary anabolic and regenerative pathways. No direct human co-administration data.
- Des(1-3)IGF-1
- Research dose post-workout (local IM)
- TB-500
- 2–5 mg SQ, 2× weekly
- Frequency
- Per research cycle
- Primary benefit
- Muscle hypertrophy, injury recovery, vascular support
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition